UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A 96-Week Comparison of Lopinavir-Ritonavir Combination Therapy Followed by Lopinavir-Ritonavir Monotherapy versus Efavirenz Combination Therapy

The Journal of infectious diseases, 2008-07, Vol.198 (2), p.234-240

2008

Volltextzugriff (PDF)

Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults

Journal of acquired immune deficiency syndromes (1999), 2017-06, Vol.75 (2), p.226-231

2017

Volltextzugriff (PDF)

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial

The lancet HIV, 2020-01, Vol.7 (1), p.e16-e26

2020

Volltextzugriff (PDF)

SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients

AIDS (London), 2004-07, Vol.18 (11), p.1529-1537

2004

Volltextzugriff (PDF)

T-1249 Retains Potent Antiretroviral Activity in Patients Who Had Experienced Virological Failure while on an Enfuvirtide-Containing Treatment Regimen

The Journal of infectious diseases, 2005-04, Vol.191 (7), p.1155-1163

2005

Volltextzugriff (PDF)

Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial

Annals of internal medicine, 2003-09, Vol.139 (5 Pt 1), p.313

2003

Volltextzugriff (PDF)

Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

The New England journal of medicine, 2014-04, Vol.370 (16), p.1483-1493

2014

Volltextzugriff (PDF)

The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation

Science (American Association for the Advancement of Science), 2010-12, Vol.330 (6010), p.1551-1557

2010

Volltextzugriff (PDF)

Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

The New England journal of medicine, 2008-10, Vol.359 (14), p.1429-1441

2008

Volltextzugriff (PDF)

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/ emtricitabine with lopinavir/ritonavir for initial HIV treatment

AIDS (London), 2009-07, Vol.23 (12), p.1547-1556

2009

Volltextzugriff (PDF)

Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection

The New England journal of medicine, 2008-10, Vol.359 (14), p.1442-1455

2008

Volltextzugriff (PDF)

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

The lancet HIV, 2018-05, Vol.5 (5), p.e211-e220

2018

Volltextzugriff (PDF)

Abacavir Expanded Access Program for Adult Patients Infected with Human Immunodeficiency Virus Type 1

Clinical infectious diseases, 2002-02, Vol.34 (4), p.535-542

2002

Volltextzugriff (PDF)

Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial

AIDS (London), 2010-01, Vol.24 (1), p.55-65

2010

Volltextzugriff (PDF)

Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients

AIDS (London), 2010-08, Vol.24 (13), p.2019-2027

2010

Volltextzugriff (PDF)

Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African Americans

Human molecular genetics, 2012-10, Vol.21 (19), p.4334-4347

2012

Volltextzugriff (PDF)

First large, multicenter, open-label study utilizing HLA-B5701 screening for abacavir hypersensitivity in North America

AIDS (London), 2008-08, Vol.22 (13), p.1673-1675

2008

Volltextzugriff (PDF)

Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial

AIDS research and human retroviruses, 2012-05, Vol.28 (5), p.437-446

2012

Volltextzugriff (PDF)

The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single‐arm, open‐label study of etravirine and darunavir/ritonavir as dual therapy in HIV‐1‐infected early treatment‐experienced subjects

HIV medicine, 2015-05, Vol.16 (5), p.288-296

2015

Volltextzugriff (PDF)

Twice-Daily Trizivir versus Combivir-Abacavir in Antiretroviral-Experienced Adults with Human Immunodeficiency Virus-1 Infection: A Formulation-Switch Trial

Pharmacotherapy, 2003-11, Vol.23 (11), p.1432-1440

2003

Volltextzugriff (PDF)

A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals : Selection of thymidine analog regimen therapy (START II)

AIDS (London), 2000-07, Vol.14 (11), p.1601-1610

2000

Volltextzugriff (PDF)

Efficacy and safety of switching suppressed patients with elevated triglycerides from lopinavir/ritonavir or fosamprenavir/ritonavir to atazanavir/ritonavir or darunavir/ritonavir based therapy: The LARD study

HIV & AIDS review, 2012-12, Vol.11 (4), p.77-83

2012

Volltextzugriff (PDF)

Lamivudine 300 mg QD Versus Continued Lamivudine 150 mg BID with Stavudine and a Protease Inhibitor in Suppressed Patients

HIV clinical trials, 2002-09, Vol.3 (5), p.361-370

2002

Volltextzugriff (PDF)

ARIES 144 Week Results: Durable Virologic Suppression in HIV-Infected Patients Simplified to Unboosted Atazanavir/Abacavir/Lamivudine

HIV clinical trials, 2012-09, Vol.13 (5), p.233-244

2012

Volltextzugriff (PDF)

Similar Efficacy of Raltegravir When Used With or Without a Protease Inhibitor in Treatment-Experienced Patients

HIV clinical trials, 2011-05, Vol.12 (3), p.131-140

2011

Volltextzugriff (PDF)

1 – 25 von 26

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(18)

Publikationsform

Artikel
(26)

Sprache

Englisch
(26)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A 96-Week Comparison of Lopinavir-Ritonavir Combination Therapy Followed by Lopinavir-Ritonavir Monotherapy versus Efavirenz Combination Therapy

Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial

SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients

T-1249 Retains Potent Antiretroviral Activity in Patients Who Had Experienced Virological Failure while on an Enfuvirtide-Containing Treatment Regimen

Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial

Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation

Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/ emtricitabine with lopinavir/ritonavir for initial HIV treatment

Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

Abacavir Expanded Access Program for Adult Patients Infected with Human Immunodeficiency Virus Type 1

Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial

Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients

Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African Americans

First large, multicenter, open-label study utilizing HLA-B5701 screening for abacavir hypersensitivity in North America

Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial

The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single‐arm, open‐label study of etravirine and darunavir/ritonavir as dual therapy in HIV‐1‐infected early treatment‐experienced subjects

Twice-Daily Trizivir versus Combivir-Abacavir in Antiretroviral-Experienced Adults with Human Immunodeficiency Virus-1 Infection: A Formulation-Switch Trial

A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals : Selection of thymidine analog regimen therapy (START II)

Efficacy and safety of switching suppressed patients with elevated triglycerides from lopinavir/ritonavir or fosamprenavir/ritonavir to atazanavir/ritonavir or darunavir/ritonavir based therapy: The LARD study

Lamivudine 300 mg QD Versus Continued Lamivudine 150 mg BID with Stavudine and a Protease Inhibitor in Suppressed Patients

ARIES 144 Week Results: Durable Virologic Suppression in HIV-Infected Patients Simplified to Unboosted Atazanavir/Abacavir/Lamivudine

Similar Efficacy of Raltegravir When Used With or Without a Protease Inhibitor in Treatment-Experienced Patients

Suchergebnisse filtern